1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394-424.
2. Irwin DE, Milsom I, Hunskaar S, Reilly K, Kopp Z, Herschorn S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol. 2006;50:1306-14; discussion 1314.
3. Lee CL, Kuo HC. Videourodynamic analysis in men with lower urinary tract symptoms: correlation between age and prostate size with lower urinary tract dysfunction. Urol Sci. 2016;27:21-5.
4. Roobol MJ, van Vugt HA, Loeb S, Zhu X, Bul M, Bangma CH, et al. Prediction of prostate cancer risk: the role of prostate volume and digital rectal examination in the ERSPC risk calculators. Eur Urol. 2012;61:577-83.
5. Benson MC, Whang IS, Pantuck A, Ring K, Kaplan SA, Olsson CA, et al. Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer. J Urol. 1992;147:815-6.
6. Porcaro AB, Tafuri A, Sebben M, Shakir A, Novella G, Pirozzi M, et al. Prostate volume index and prostatic chronic inflammation have an effect on tumor load at baseline random biopsies in patients with normal DRE and PSA values less than 10 ng/ml: results of 564 consecutive cases. Ther Adv Urol. 2019;11:1756287219868604.
7. Nordström T, Akre O, Aly M, Grönberg H, Eklund M. Prostate-specific antigen (PSA) density in the diagnostic algorithm of prostate cancer. Prostate Cancer Prostatic Dis. 2018;21:57-63.
8. Erdogan A, Polat S, Keskin E, Turan A. Is prostate volume better than PSA density and free/total PSA ratio in predicting prostate cancer in patients with PSA 2.5–10 ng/mL and 10.1–30 ng/mL? Aging Male. 2020;23:59-65.
9. Zlotta AR, Djavan B, Marberger M, Schulman CC. Prostate specific antigen density of the transition zone: a new effective parameter for prostate cancer prediction. J Urol. 1997;157:1315-21.
10. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280:969-74.
11. Kalish J, Cooner WH, Graham SD Jr. Serum PSA adjusted for volume of transition zone (PSAT) is more accurate than PSA adjusted for total gland volume (PSAD) in detecting adenocarcinoma of the prostate. Urology. 1994;43:601-6.
12. Freedland SJ, Isaacs WB, Platz EA, Terris MK, Aronson WJ, Amling CL, et al. Prostate size and risk of high-grade, advanced prostate cancer and biochemical progression after radical prostatectomy: a search database study. J Clin Oncol. 2005;23:7546-54.
13. Freedland SJ, Wieder JA, Jack GS, Dorey F, deKernion JB, Aronson WJ. Improved risk stratification for biochemical recurrence after radical prostatectomy using a novel risk group system based on prostate specific antigen density and biopsy Gleason score. J Urol. 2002;168:110-5.
14. Alcaraz A, Hammerer P, Tubaro A, Schröder FH, Castro R. Is there evidence of a relationship between benign prostatic hyperplasia and prostate cancer? Findings of a literature review. Eur Urol. 2009;55:864-73.
15. Prakash K, Pirozzi G, Elashoff M, Munger W, Waga I, Dhir R, et al. Symptomatic and asymptomatic benign prostatic hyperplasia: molecular differentiation by using microarrays. Proc Natl Acad Sci U S A. 2002;99:7598-603.
16. Hammarsten J, Högstedt B. Hyperinsulinaemia: a prospective risk factor for lethal clinical prostate cancer. Eur J Cancer. 2005;41:2887-95.
17. Irani J, Lefebvre O, Murat F, Dahmani L, Doré B. Obesity in relation to prostate cancer risk: comparison with a population having benign prostatic hyperplasia. BJU Int. 2003;91:482-4.
18. Nandeesha H, Koner BC, Dorairajan LN, Sen SK. Hyperinsulinemia and dyslipidemia in non-diabetic benign prostatic hyperplasia. Clin Chim Acta. 2006;370:89-93.
19. Wolff JM, Scholz A, Boeckmann W, Jakse G. Differentiation of benign prostatic hyperplasia and prostate cancer employing prostatic-specific antigen density. Eur Urol. 1994;25:295-8; discussion 304.
20. Elliott CS, Shinghal R, Presti JC. The performance of prostate specific antigen, prostate specific antigen density and transition zone density in the era of extended biopsy schemes. J Urol. 2008;179:1756-61; discussion 1761.
21. Lee J, Yang SW, Jin L, Lee CL, Lee JY, Shin JH, et al. Is PSA density of the peripheral zone as a useful predictor for prostate cancer in patients with gray zone PSA levels? BMC Cancer. 2021;21:472.
22. Verma A, Onge JS, Dhillon K, Chorneyko A. PSA density improves prediction
of prostate cancer. Can J Urol. 2014;10.
23. Wang C, Wang YY, Wang SY, Ding JX, Ding M, Ruan Y, et al. Peripheral zone PSA density: a predominant variable to improve prostate cancer detection efficiency in men with PSA higher than 4 ng ml–1. Asian J Androl. 2021;23:415-20.
24. Aksoy Y, Oral A, Aksoy H, Demirel A, Akcay F. PSA density and PSA transition zone density in the diagnosis of prostate cancer in PSA gray zone cases. Ann Clin Lab Sci. 2003;33:320-3.
25. Liu J, Wang ZQ, Li M, Zhou MY, Yu YF, Zhan WW. Establishment of two new predictive models for prostate cancer to determine whether to require prostate biopsy when the PSA level is in the diagnostic gray zone (4–10 ng ml− 1). Asian J Androl. 2020;22:213-6.
26. Loeb S, Catalona WJ. The Prostate Health Index: a new test for the detection of prostate cancer. Ther Adv Urol. 2014;6:74-7.
27. Carroll PH, Mohler JL. NCCN guidelines updates: prostate cancer and prostate cancer early detection. J Natl Compr Canc Netw. 2018;16:620-3.
28. Chiu ST, Cheng YT, Pu YS, Lu YC, Hong JH, Chung SD, et al. Prostate health index density outperforms prostate health index in clinically significant prostate cancer detection. Front Oncol. 2021;11:772182.
29. Richardson TD, Wojno KJ, Liang LW, Giacherio DA, England BG, Henricks WH, et al. Half-life determination of serum free prostate-specific antigen following radical retropubic prostatectomy. Urology. 1996;48:40-4.
30. Aprikian S, Luz M, Brimo F, Scarlata E, Hamel L, Cury FL, et al. Improving ultrasound-based prostate volume estimation. BMC Urol. 2019;19:68.